Is Sandu Pharma. overvalued or undervalued?

As of 18 September 2025, Sandu Pharma's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued based on its financial metrics. Key ratios include a PE ratio of 29.69, an EV to EBITDA of 16.05, and a Price to Book Value of 1.10, which suggest that the stock is trading at a reasonable valuation compared to its earnings and book value.
In comparison with peers, Sandu Pharma's PE ratio is significantly lower than that of Elitecon International, which is marked as very expensive at 406.28, and MMTC, which is risky at 140.99. Additionally, PTC India, deemed very attractive, has a much lower PE of 8.32, highlighting Sandu Pharma's relative valuation appeal within the sector. Despite recent underperformance against the Sensex, particularly over the past year with a decline of 25.67% compared to a slight increase of 0.08% for the index, the current valuation metrics suggest that Sandu Pharma presents a compelling investment opportunity.